My Ocular Melanoma has no actionable mutations, what are my options

Treatment Options for Ocular Melanoma Without Actionable Mutations

I understand this can feel limiting, but having no actionable mutations doesn't mean you lack treatment options. Let me explain what this means and what pathways are available to you.

What "No Actionable Mutations" Means

When genetic testing shows no actionable mutations, it means your tumor doesn't have specific genetic changes (like BRAF, KIT, or GNAQ mutations) that would make it responsive to targeted therapies—drugs designed to attack those specific mutations. However, this is actually common in uveal melanoma. According to NCCN Guidelines for Uveal Melanoma, many uveal melanomas don't carry the same mutations found in cutaneous (skin) melanomas, so you're not alone in this situation.

Your Treatment Options

1. For Localized (Non-Metastatic) Disease

If your melanoma is still in the eye and hasn't spread, the primary treatment options include:

Radiation Therapy Options:

• Plaque brachytherapy (radioactive plaque placed on the eye)
• Particle beam radiation (proton or helium ion therapy)
• Stereotactic radiosurgery (SRS) for select cases

According to NCCN Guidelines, these radiation approaches are effective in preventing local recurrence in greater than 85% of cases and can preserve your vision and eye.

Surgical Options:

• Enucleation (eye removal) - typically reserved for large tumors, neovascular glaucoma, or when vision cannot be preserved
• Surgical resection - for small, select tumors

Other Local Therapies:

• Laser therapy (transpupillary thermotherapy)
• Cryotherapy (freezing)
• Photodynamic therapy

Your ophthalmologic oncologist will determine which approach fits your specific tumor size, location, and other factors.

---

2. For Metastatic Disease (If Spread Has Occurred)

This is where treatment becomes more complex, but several options exist:

Immunotherapy (Checkpoint Inhibitors)

These drugs help your immune system recognize and attack cancer cells:

• Nivolumab + Ipilimumab combination - According to NCCN Guidelines, two phase II trials showed this combination had response rates between 6-38% in metastatic uveal melanoma patients
• Single-agent nivolumab or pembrolizumab - Anti-PD-1 agents showing modest activity

Important context: Response rates are lower than in cutaneous melanoma, but some patients do respond. The benefit may be longer survival even without dramatic tumor shrinkage.

Tebentafusp (Immunotherapy - Most Promising Recent Option)

This is a specialized immunotherapy that targets a protein called gp100 found on melanoma cells. According to NCCN Guidelines, a large phase III trial showed:

• 1-year overall survival: 73% with tebentafusp vs. 59% with standard treatments
• Progression-free survival: 31% vs. 19%

Important note: This requires HLA-A*02:01 testing (a genetic marker). It can cause cytokine-release syndrome, so hospitalization for monitoring is needed, especially early on.

MEK Inhibitors

• Trametinib - According to NCCN Guidelines, while data are strongest for selumetinib (not yet FDA-approved for this use), trametinib is included as a recommended option based on the general lack of systemic therapy options for uveal melanoma

Liver-Directed Therapies (If Liver Metastases)

Since the liver is the most common site of metastasis:

• Hepatic arterial infusion (HAI) chemotherapy
• Surgical resection of liver metastases
• Ablation techniques

According to NCCN Guidelines, meta-analyses suggest localized treatment (surgery or liver-directed therapies) results in better outcomes than systemic therapy alone for metastatic disease.

Chemotherapy

Traditional chemotherapy options exist but have shown limited activity (response rates <10% in most studies). These might be considered if other options aren't suitable.

---

Important Questions to Ask Your Oncology Team

1. What is the stage and location of my tumor? (This determines which treatments apply to you)

2. Have I been tested for HLA-A*02:01? (This determines if tebentafusp is an option)

3. If I have metastatic disease, where are the metastases located? (Liver metastases may benefit from liver-directed therapy rather than systemic treatment)

4. What clinical trials might I be eligible for? (New treatments are constantly being studied)

5. What is your recommendation for surveillance/monitoring? (Even without actionable mutations, regular imaging is important)

6. Are there any emerging therapies you think I should know about? (The field is evolving)

---

The Bottom Line

While lacking actionable mutations means you won't benefit from targeted therapies like BRAF or KIT inhibitors, you have several meaningful treatment pathways:

• For localized disease: Radiation and surgical options are highly effective
• For metastatic disease: Immunotherapy (especially tebentafusp), MEK inhibitors, and liver-directed therapies offer real options

According to NCCN Guidelines, the key is matching the right treatment to your specific disease stage and location. Your care team will help determine which approach is best for YOUR situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.